Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARA | Q07869 | 5/20 | 0.60 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.60 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.60 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.60 |
| ▸ | TSHR | P16473 | 1/20 | 0.60 |
| ▸ | HTR2A | P28223 | 1/20 | 0.60 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.60 |
| ▸ | FBP1 | P09467 | 9/20 | 0.49 |
| ▸ | PPARG | P37231 | 4/20 | 0.45 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3371452 | 0.87 | PPARA (0.61) | PPARAABCB11CYP1A2CYP3A4TSHR | |
| SCHEMBL611776 | 0.84 | PPARA (0.67) | PPARAABCB11CYP1A2CYP3A4TSHR | |
| SCHEMBL610263 | 0.84 | PPARA (0.58) | PPARAABCB11CYP1A2CYP3A4TSHR | |
| SCHEMBL31067888 | 0.82 | PPARA (0.56) | PPARAABCB11CYP1A2CYP3A4TSHR | |
| SCHEMBL25262066 | 0.82 | PPARA (0.56) | PPARAABCB11CYP1A2CYP3A4TSHR | |
| SCHEMBL16248094 | 0.81 | PPARA (0.55) | PPARAABCB11CYP1A2CYP3A4TSHR | |
| SCHEMBL199420 | 0.80 | PPARA (0.73) | PPARAABCB11CYP1A2CYP3A4TSHR | |
| SCHEMBL11548436 | 0.78 | PPARA (0.76) | PPARAABCB11CYP1A2CYP3A4TSHR | |
| SCHEMBL3903999 | 0.78 | PPARA (0.76) | PPARAABCB11CYP1A2CYP3A4TSHR | |
| SCHEMBL198509 | 0.77 | PPARA (0.50) | PPARAABCB11CYP1A2CYP3A4TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2321282-B1 | NEW BENZIMIDAZOLE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2013-03-27 | — | — | EP | disclosed |
| US-8088930-B2 | Benzimidazole derivatives | HOFFMANN-LA ROCHE INC. (US) | 2012-01-03 | — | — | US | disclosed |
| EP-2321282-A1 | NEW BENZIMIDAZOLE DERIVATIVES | F. Hoffmann-La Roche AG (CH) | 2011-05-18 | — | — | EP | disclosed |
| WO-2010028981-A1 | NEW BENZIMIDAZOLE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2010-03-18 | — | — | WO | disclosed |
| US-20100063101-A1 | NEW BENZIMIDAZOLE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2010-03-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100063101-A1 | NEW BENZIMIDAZOLE DERIVATIVES | CYP3A7, ECI1, CYP2B6 | PPARA 322/4885ABCB11 43/4885CYP1A2 54/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.